S‐AML patients were reported to carry less NPM1 mutations and FLT3‐ITD.26, 27 Besides, patients with AML secondary to MDS and CMML carried more ASXL1 and NRAS mutations.27 Currently, a prospective study including more molecular events is performed in our center, which will provide more integrated results concerning the distribution and prognostic significance of molecular alterations in e/s‐AML patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.